2006
DOI: 10.1158/0008-5472.can-06-0631
|View full text |Cite
|
Sign up to set email alerts
|

In vivo Tumor Targeting Using a Novel Intestinal Pathogen-Based Delivery Approach

Abstract: Efficient methods for tumor targeting are eagerly awaited and must satisfy several challenges: molecular specificity, transport through physiologic barriers, and capacity to withstand extracellular or intracellular degradation and inactivation by the immune system. Through interaction with its hosts, the intestinal pathogen-produced Shiga toxin has evolved molecular properties that are of interest in this context. Its nontoxic B-subunit binds to the cellular toxin receptor, glycosphingolipid Gb 3 , which is hi… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

6
79
0
1

Year Published

2007
2007
2013
2013

Publication Types

Select...
8

Relationship

5
3

Authors

Journals

citations
Cited by 68 publications
(86 citation statements)
references
References 36 publications
6
79
0
1
Order By: Relevance
“…In another study, 6 out of 21 patients with diarrhea induced by S. dysenteriae had antibodies to Shiga holotoxin, but none to STxBderived peptides (29). Our own preclinical data on mouse models for CRC indicate that repeated uptake of STxB by the oral or intravenous route is well tolerated and does not cause adverse side effects (30).…”
Section: Introductionmentioning
confidence: 94%
See 1 more Smart Citation
“…In another study, 6 out of 21 patients with diarrhea induced by S. dysenteriae had antibodies to Shiga holotoxin, but none to STxBderived peptides (29). Our own preclinical data on mouse models for CRC indicate that repeated uptake of STxB by the oral or intravenous route is well tolerated and does not cause adverse side effects (30).…”
Section: Introductionmentioning
confidence: 94%
“…In the present study, we expanded our previously published preclinical investigations (30) to human tumors. Instead of using established tumor cell lines that have been cultured for long periods of time, potentially leading to the acquisition of multiple genetic aberrations, we decided to study primary cultures of human tumor cells of the colon and rectum.…”
Section: Introductionmentioning
confidence: 99%
“…This facilitates the use of StxB as a vector for peptide delivery to the MHC class I pathway for the development of vaccines against specific cancer epitopes (for reviews see [121,123]). It has been shown that exogenous antigens coupled to StxB is targeted to the MHC class I pathway and then presented on the surface of dendritic cells, facilitating activation of cytotoxic T-cells and antitumor immunity [124][125][126]. In this way StxB might function as a non-live, non-toxic vaccine delivery system in cancer therapy.…”
Section: Exploitation Of Stx In Medicinementioning
confidence: 99%
“…For diagnostic purposes and selective imaging of these Gb3-expressing cells, visualizing agents, such as radioactive isotopes, contrast agents or fluorescent dyes, might be coupled to StxB. It has been demonstrated that labeled StxB administered systemically in mouse models accumulates in tumor regions overexpressing Gb3, thus confirming that cancer cells can be targeted in vivo by StxB [124,127].…”
Section: Exploitation Of Stx In Medicinementioning
confidence: 99%
“…Transport to the ER is believed to be required for translocation of the A-subunit to the cytosol where its molecular target -ribosomal RNA -resides [12]. STxB has been used as a tool for the characterization of the retrograde route [13,14], and in biomedical research as a delivery tool for immunotherapy [3,15] and cancer targeting [16,17]. It was shown that STxB delivers exogenous peptides into the MHC class I and II pathways of human and mouse dendritic cells (DCs) and induces humoral and cell-mediated immune responses that protect mice from tumor growth [18][19][20][21][22].…”
Section: Introductionmentioning
confidence: 99%